Assessment of the High Incidence of COVID-19 in Vaccinated and Unvaccinated Individuals and its Relationship with Several Physical Indicators
Keywords:
COVID-19 , Patient symptoms , Vaccination, Physical indicatorsAbstract
COVID-19 vaccines have shown good efficiency in clinical routs, but some people may be infected after vaccination. The objective of the present study was to review the risk factors for COVID-19 infection after vaccination and to define the characteristics of the disease post-vaccination. her survey was conducted among 451 participants of both sexes, ranging in age from 18 to over 60 years, and also included information about COVID-19 patients, including their weight, blood type, geographic location, symptoms, diagnosis, health risk factors, and duration of infection. In our study, people vaccinated with COVID-19 vaccines (Pfizer, Sinopharm, and AstraZeneca) showed fewer symptoms compared to those who were unvaccinated, with the Pfizer vaccine being particularly effective in reducing symptoms. The degree of persistence of symptoms was reduced. There was an increase in those with chronic conditions, but by less than a month indicating that vaccination may mitigate the severity and duration of symptoms in COVID-19 patients.
References
Ad’hiah, A. H.; Abdullah, M. H.; Alsudani, M. Y.; Shnawa, R. M. S.; AlSa’ady, A. J. R.; Allami, R. H.; et al.; “Association between ABO blood groups and susceptibility to COVID-19: profile of age and gender in Iraqi patients”. Egyptian Journal of Medical Human Genetics, 21: 76, 2020.
Antonelli, M.; Penfold, R. S.; Merino, J.; Sudre, C. H.; Molteni, E.; Berry, S.; Canas, L. S.; Graham, M. S.; et al.; “Risk factors and disease profile of postvaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case‒control study”. The Lancet Infectious Diseases, 22(1): 43–55, 2022.
Babicki, M.; Malchrzak, W.; Hans-Wytrychowska, A.; Mastalerz-Migas, A.; “Impact of Vaccination on the Sense of Security, the Anxiety of COVID-19 and Quality of Life among Polish. A Nationwide Online Survey in Poland”. Vac., 9(12): 1444, 2021.
Cavanaugh, A.M.; Spicer, K.B.; Thoroughman, D.; Glick, C.; Winter, K.; “Reduced Risk of Reinfection with SARS-CoV-2 After COVID-19 Vaccination- Kentucky, Morbidity and Mortality Week”. Rep., 70: 1081-1083, 2021.
Feikin, D. R.; Higdon, M. M.; Abu-Raddad, L. J.; Andrews, N.; Araos, R.; Goldberg, Y.; et al.; “Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression”. Lancet, 399(10328): 924–944, 2022.
Idan, E. M.; Ahmed, Z. A.; Ardalan, N. M.; “Persistent symptoms in an Iraqi patient sample after infection with COVID-19”. Teikyo Medical Journal, 44(4):1054-1055, 2021.
Jamal, O.W.; Abady, N.H.; Taher, N.M.; “A Retrospective Study Regarding Coronavirus Disease Epidemiological Features among People in Fallujah City, Iraq”. Iraqi Journal of Medical Science, 20(2): 201-206, 2022.
Kaswa, R.; “Vaccine Breakthrough Infections of SARS-CoV-2: A Case Report”. Ethiopian Journal of Health Science, 32(1): 201–204, 2022.
Khudhr, E. N.; and Shehab, Z. H.; “Rapid Identification of some typical and atypical Pneumonia coinfections associated with COVID-19 patients by a real -time PCR assay”. Iraqi Journal of Biotechnology, 21(2): 331-340, 2022.
Krithika, L. B.; “Paradigm Shift Toward Federated Learning for COVID-19 Detection: A Survey”. Iraqi Journal of Science, 64(7): 3596-3612, 2023.
Larijani, M. S.; Ashrafian, F.; Amiri, F. B.; Banifazl, M.; Bavand, A.; Karami, A.; Asgari, F.; “Characterization of long COVID-19 manifestations and its associated factors: A prospective cohort study from Iran”. Microbial Pathogenesis, 169: 105618, 2022.
Malik, J. A.; Ahmed, S.; Mir, A.; Shinde, M.; Bender, O.; Alshammari, F.; Ansari, M.; Anwar, S.; “The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges”. Journal of Infection and Public Health, 15(2): 228–240, 2022.
Mohammed, I.; Nauman, A.; Paul, P.; Ganesan, S.; Chen, K. H.; Jalil, S. M. S.; et al.; “The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review”. Human Vaccines & Immunotherapeutics, 18(1): 2027160, 2022.
MOH-Iraq. Iraqi Ministry of Health. Retrieved July 31, 2020. https://moh.gov.iq/ pdf
Notarte, K.I.; Catahay, J. A.; Velasco, J. V.; Pastrana, A.; Therese Ver, A.; Pangilinan, F. C.; et al.; “Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms”. Systematic Review, 53: 1-19, 2022.
Rahimi, A.; Mirzazadeh, A.; Tavakolpour, S.; “Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection”. Genomics, 113(1): 1221-1232, 2021.
SAS. Statistical Analysis System, User's Guide. Statistical. Version 9.6th ed. SAS. Inst. Inc. Cary. N.C. USA,2018.
Sumantri, S.; Rengganis, I.; “Immunological dysfunction and mast cell activation syndrome in long COVID-19 patients”. Asia Pacif. Aller., 13(1): 50–53, 2023.
World Health Organization (WHO). Novel coronavirus (2019-nCoV). Situation report. 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200207-sitrep-18-ncov.pdf?sfvrsn=fa644293_2.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Shatha T. Ahmed, Zina H. Shehab, Sana MH Al-Shimmary, Emad H. Jassim, Mena A. M. Amen
This work is licensed under a Creative Commons Attribution 4.0 International License.
.jpg)
